Search Results
Jul 27, 2026, 08:00 ET Leidos demonstrates tactical cyber detection capability during Valiant Shield 2026
July 2 in Guam, Leidos' Cyber and Electromagnetic Activities Resiliency System (CRS) detected simulated cyber intrusions and identified unusual activities across tactical platforms and networks. The demonstration showed how CRS can help military teams identify possible cyber threats before they affect the
More news about: Leidos Holdings, Inc.
Jul 23, 2026, 08:30 ET TECVAYLI® + TALVEY® reduced the risk of disease progression or death by 89% and the risk of death by 62% in earlier-line relapsed/refractory multiple myeloma
SYNDROMECytokine release syndrome (CRS), including life-threatening or fatal reactions, can occur in patients receiving TECVAYLI. Initiate treatment with TECVAYLI step-up dosing schedule to reduce risk of CRS. Withhold TECVAYLI until CRS resolves or permanently discontinue based on severity.Neurologic
More news about: Johnson & Johnson
Jul 22, 2026, 07:00 ET Coleman® and Kane Brown Celebrate Multi-Year Partnership with the Launch of Limited-Edition Collection
Award win.Brown has also earned numerous accolades for his ongoing work with The Boys & Girls Club, including the Country Radio Seminar (CRS) Humanitarian Award and the Champion of Youth Award from The Boys & Girls Club.MEDIA CONTACTS:Alison Brod Marketing
More news about: Newell Brands
Jul 20, 2026, 03:00 ET Antengene Announces Poster Presentation of ATG-022 and ATG-037 at ESMO 2026
for low expressing targets, steric hindrance masking, and proprietary CD3 sequences with fast on/off kinetics to minimize cytokine release syndrome (CRS) and enhance efficacy. These characteristics support the platform's broad applicability across autoimmune disease, solid tumors and hematological malignancies,
More news about: Antengene Corporation Limited
Jul 15, 2026, 08:55 ET Anand Systems Inc. Launches ASI RMS Powered by Duetto for Worldwide Intelligent Revenue Optimization
globally, ASI provides a comprehensive suite of solutions including Property Management Systems (PMS), Channel Manager, Central Reservation System (CRS), Payment Processing, Revenue Management, and other hotel technology solutions designed to help properties operate more efficiently and profitably.About Duetto
More news about: Anand Systems Inc.
Jul 15, 2026, 05:00 ET Cambium Networks Wi-Fi Delivers Connectivity Aboard the International Space Station
The access points were carried to the ISS aboard a SpaceX Commercial Resupply Services mission for NASA (CRS-30) and installed in the station's Node 1 (Unity) and Node 2 (Harmony) modules. The Cambium solution provides the wireless backbone for nearly every
More news about: Cambium Networks
Jul 14, 2026, 10:00 ET Modera Wealth Management Hires Two New Chiefs to Lead Investments and Operations
www.adviserinfo.sec.gov) to obtain a copy of our disclosure statement, Form ADV Part 2A, and ADV Part 3/Form CRS. In addition, our Privacy Notice outlines how we handle your non-public personal information. Please read these documents carefully before you make a
More news about: Modera Wealth Management, LLC
Jul 13, 2026, 00:00 ET Antengene Announces Receipt of USD 60 Million Upfront Payment from UCB
for low expressing targets, steric hindrance masking, and proprietary CD3 sequences with fast on/off kinetics to minimize cytokine release syndrome (CRS) and enhance efficacy. These characteristics support the platform's broad applicability across autoimmune disease, solid tumors and hematological malignancies,
More news about: Antengene Corporation Limited
Jul 09, 2026, 10:31 ET Systemic Lupus Erythematosus Market at a Turning Point as 6 Late-Stage Emerging Therapies Set to Redefine Treatment Landscape | DelveInsight
autoleucel, and resecabtagene autoleucel, show strong potential in SLE by inducing deep B-cell depletion and durable remission, though safety risks such as CRS and ICANS require intensive monitoring.Reflecting the growing innovation and expanding therapeutic opportunities in this space, DelveInsight
More news about: DelveInsight Business Research, LLP
Jul 06, 2026, 13:45 ET AbbVie Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma
useCytokine release syndrome (CRS)CRS, which may be life-threatening or fatal, occurred in patients receiving Tepkinly. The most common signs and symptoms of CRS include pyrexia, hypotension and hypoxia. Other signs and symptoms of CRS in more than two patients include chills,
More news about: AbbVie
Jul 06, 2026, 13:45 ET AbbVie Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma
useCytokine release syndrome (CRS)CRS, which may be life-threatening or fatal, occurred in patients receiving Tepkinly. The most common signs and symptoms of CRS include pyrexia, hypotension and hypoxia. Other signs and symptoms of CRS in more than two patients include chills,
More news about: AbbVie
Jun 29, 2026, 16:52 ET AbbVie Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
serious side effects, including:Cytokine release syndrome (CRS), which is common during treatment with EPKINLY and can be serious or lead to death. To help reduce your risk of CRS, you will receive EPKINLY on a step-up dosing schedule (when you receive 2 smaller step-up
More news about: AbbVie
Jun 29, 2026, 16:15 ET AbbVie Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
serious side effects, including:Cytokine release syndrome (CRS), which is common during treatment with EPKINLY and can be serious or lead to death. To help reduce your risk of CRS, you will receive EPKINLY on a step-up dosing schedule (when you receive 2 smaller step-up
More news about: AbbVie
Jun 29, 2026, 04:47 ET Ever Supreme Launches Phase IIa Clinical Trial for CAR001, Accelerating Global Market Expansion
chemo comes at a heavy cost, significantly increasing the patient's risk of infection and causing side effects like anemia, cytokine release syndrome (CRS), neurotoxicity, and general chemotherapy toxicity. Ever Supreme points out that by eliminating the need for lymphodepletion, CAR001 vastly improves
More news about: Ever Supreme Bio Technology Co., Ltd.
Jun 24, 2026, 08:00 ET Becoming rentABLE Joins Novartis' "SMAshing My Limits And Going Places" Campaign to Expand Accessible Lodging for People Living with SMA
https://www.congress.gov/crs-product/IF12920.US Senate Special Committee on Aging. Chairman Bob Casey Opening Statement: Laying the Foundation: Housing Accessibility
More news about: Becoming rentABLE
Jun 22, 2026, 23:56 ET China Resources Group Participates in the 4th CISCE, Unveils "China Resources Low-Carbon Eco-Community"
Chain Zone highlights green practices in low-carbon manufacturing and photovoltaic green electricity. The Health Protection Supply Chain Zone presents CR's integrated healthcare industry layout. The Technology and Smart Manufacturing Supply Chain Zone showcases core technology breakthroughs in advanced
More news about: China Resources Group
Jun 21, 2026, 20:30 ET Antengene Announces Exclusive License Agreement with MPM BioImpact-Established K2 Therapeutics for ATG-106 and Option for Undisclosed Bispecific TCE
for low expressing targets, steric hindrance masking, and proprietary CD3 sequences with fast on/off kinetics to minimize cytokine release syndrome (CRS) and enhance efficacy. These characteristics support the platform's broad applicability across autoimmune disease, solid tumors and hematological malignancies,
More news about: Antengene Corporation Limited
Jun 21, 2026, 20:00 ET Innovent Biologics Announces First Patient Dosed in a Phase 3 Clinical Trial of IBI3003(GPRC5D/BCMA/CD3 Tri-specific Antibody) for the Treatment of Multiple Myeloma
next-generation sequencing, with a threshold of 10-5, performed at a central laboratory.All cases of cytokine release syndrome (CRS) were Grade 1-2, with only 2 cases of Grade 1-2 immune effector cell-associated neurotoxicity syndrome (ICANS) reported. Most treatment-emergent adverse
More news about: Innovent Biologics
Jun 16, 2026, 09:00 ET Modera Wealth Management Expands Florida Presence with Northstar Transaction
www.adviserinfo.sec.gov) to obtain a copy of our disclosure statement, Form ADV Part 2A, and ADV Part 3/Form CRS. In addition, our Privacy Notice outlines how we handle your non-public personal information. Please read these documents carefully before you make a
More news about: Modera Wealth Management, LLC
Jun 15, 2026, 17:09 ET NAMI Elects New 2026-2027 Board Leadership to Advance Mental Health for All
Graves – NAMI Metropolitan Baltimore (MD)Rebecca Kiessling, CAE – NAMI Northern VirginiaRay Lay, CHW/CRS – NAMI IndianaBabu George Mathew – NAMI ColoradoBenjamin McAfee – NAMI Hall County (GA)Linh
More news about: National Alliance on Mental Illness (NAMI)
Jun 15, 2026, 08:00 ET Dominari Securities Raises $200,000,000.00 in World's Largest IPO
all of the principal invested. You can check the background of Dominari Securities and its registered investment professionals and review its SEC Form CRS on FINRA's BrokerCheck site at
More news about: Dominari Holdings Inc.
Jun 14, 2026, 20:15 ET CARsgen Presents Allogeneic CAR T-cell Products CT0596 and CT1190B at EHA 2026
adverse events (TEAEs), primarily hematologic toxicities, which are common adverse events following CAR-T infusion. No grade ≥3 cytokine release syndrome (CRS), no immune effector cell-associated neurotoxicity syndrome (ICANS) and no graft-versus-host disease (GVHD) were observed. No treatment-related deaths
More news about: CARsgen Therapeutics
Jun 13, 2026, 06:33 ET New TALVEY® (talquetamab-tgvs) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) data demonstrate the strength of a bispecific combination in earlier-line relapsed or refractory multiple myeloma
SYNDROMECytokine release syndrome (CRS), including life-threatening or fatal reactions, can occur in patients receiving TALVEY®. Initiate TALVEY® treatment with step-up dosing to reduce the risk of CRS. Withhold TALVEY® until CRS resolves or permanently discontinue
More news about: Johnson & Johnson
Jun 11, 2026, 10:00 ET Airiver Medical Treats First Patient in Pivotal Clinical Study of the Airiver Drug Coated Balloon for Patients with Chronic Rhinosinusitis
bringing this therapy to patients who are seeking a long-term option."CRS is defined as long-term (present for a minimum of three months despite intervention) symptomatic inflammation of the nose and paranasal sinuses. CRS is one of the most common chronic medical conditions in the world, with more
More news about: Airiver Medical
Jun 09, 2026, 21:00 ET Antengene Receives IND Approval for ATG-201 (CD19 × CD3 TCE) in Autoimmune Disease in China
for low expressing targets, steric hindrance masking, and proprietary CD3 sequences with fast on/off kinetics to minimize cytokine release syndrome (CRS) and enhance efficacy. These characteristics support the platform's broad applicability across autoimmune disease, solid tumors and hematological malignancies,
More news about: Antengene Corporation Limited